AVTX Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 58% planned / 42% discretionary
Largest single sale: $753.3K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | Sell 10b5-1 | 10,185 | $17.62 | $179.5K | 39,900 −20.3% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 679 | $20.00 | $13.6K | 51,776 −1.3% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell | 31,031 | $20.05 | $622.3K | 39,900 −43.7% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell 10b5-1 | 37,945 | $19.85 | $753.3K | 43,649 −46.5% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell | 3,749 | $19.94 | $74.8K | 39,900 −8.6% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 1,000 | $20.00 | $20.0K | 51,776 −1.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.